Senti Biosciences, Inc. - SNTI STOCK NEWS

Senti Biosciences (SNTI) reported significant advancements in its therapeutic pipeline, particularly with the upcoming IND application for SENTI-202 aimed at treating hematologic malignancies including AML and MDS, scheduled for submission in H2 2023. The company holds $98.6 million in cash and equivalents as of December 31, 2022, ensuring operational funding through at least Q1 2024. Research and development expenses increased to $34.1 million in 2022, compounded by substantial general and administrative costs of $40.8 million. The company recorded a net loss of $58.2 million for the year. Overall, Senti is positioned for ongoing growth with its innovative Gene Circuit technology.

Senti Biosciences (Nasdaq: SNTI) announces acceptance of three abstracts for presentation at the AACR Annual Meeting, scheduled for April 14-19, 2023, in Orlando, Florida. The abstracts focus on Senti Bio's proprietary CAR-NK cell therapies targeting hematologic malignancies and solid tumors. Notably, SENTI-202 is a logic gated CAR-NK cell therapy aimed at treating CD33/FLT3+ malignancies, with an IND submission planned for the second half of 2023. Additionally, data will showcase the enhanced capabilities of CAR-NK therapies through the incorporation of calibrated release IL-15. The presentations underline Senti Bio's innovative approaches and strategic partnerships to address oncology challenges.

Senti Biosciences, Inc. (Nasdaq: SNTI) announced the grant of stock options to 13 new employees, totaling 309,000 shares at an exercise price of $1.81, effective February 1, 2023. This action aligns with NASDAQ Listing Rule 5635(c)(4) and the 2022 Inducement Equity Plan. Senti Bio aims to innovate cell and gene therapies using its proprietary Gene Circuit technology, targeting complex diseases. Its lead candidate, SENTI-202, focuses on hematologic malignancies, while SENTI-401 addresses colorectal cancer and other CEA-positive cancers. The company has partnerships with Spark Therapeutics and BlueRock Therapeutics to enhance its capabilities.

Senti Biosciences, Inc. (Nasdaq: SNTI) announced its Co-Founder and CEO, Tim Lu, MD, PhD, will present at the virtual SVB Securities Global Biopharma Conference from February 13-16, 2023. Lu’s presentation is scheduled for February 16 at 3:40 PM ET. A live webcast can be accessed at this link and will be available for 90 days post-event. Senti Bio is advancing its Gene Circuit technology platform, targeting challenging cancers with its lead candidate, SENTI-202, and other programs like SENTI-401. For more details, visit Senti Bio's website.

Senti Biosciences (Nasdaq: SNTI) has announced a strategic focus on its lead oncology candidates, SENTI-202 and SENTI-401, for treating acute myeloid leukemia (AML) and colorectal cancer, respectively. The company is on track for an IND filing of SENTI-202 in the second half of 2023 and has extended its cash runway through at least Q1 2024. While the development of SENTI-301A for hepatocellular carcinoma (HCC) is deprioritized, Senti Bio aims to establish partnerships for its clinical progression. The advancements in gene circuit technology are expected to enhance therapy precision and effectiveness.

Senti Biosciences (Nasdaq: SNTI) will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 5:15 p.m. PT. Tim Lu, MD, PhD, Co-founder and CEO, will lead the presentation. The event can be viewed via webcast on the company’s website. Senti Bio is focused on developing next-generation cell and gene therapies using its innovative gene circuit platform. Their lead candidate, SENTI-202, targets hematologic malignancies, while SENTI-301A addresses hepatocellular carcinoma and other cancers.

Senti Biosciences announced at the ASH Annual Meeting progress on SENTI-202, an off-the-shelf CAR-NK cell therapy, showcasing preclinical data indicating effective targeting of CD33 and FLT3 expressing tumors, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

The candidate is on track for an IND filing in 2H 2023. The data demonstrates significant cancer-killing activity in vitro and in vivo, while protecting healthy cells. This development highlights the potential for SENTI-202 to revolutionize treatment for patients with these hematologic malignancies.

Senti Biosciences, Inc. (Nasdaq: SNTI) will host an Investor Event on December 11, 2022, from 11:30 a.m. to 12:30 p.m. CST during the 64th ASH Annual Meeting in New Orleans, LA. The event will cover preclinical data and clinical plans for SENTI-202 aimed at treating hematologic malignancies like AML. Notable speaker Stephen A. Strickland, Jr., MD, will discuss the treatment landscape. Attendance is available in-person and virtually, with a webcast accessible on Senti's Events page.

The meeting is independent from the official ASH program.

Senti Biosciences reported progress in its clinical pipeline with SENTI-202 and SENTI-301A targeting hematologic and solid tumors, respectively. The company expects to file IND applications for both candidates in 2023. As of September 30, 2022, Senti Bio had $114.9 million in cash, projected to sustain operations into 2024. The third-quarter net loss was $16.6 million, or $0.38 per share, with increased R&D and G&A expenses. Notably, the company highlighted promising preclinical data at the SITC Annual Meeting, reinforcing its innovative gene circuit technology.